The path from clinical trials to patient access

Learn about the drug development process in Canada and how new drugs get to patients. The information presented here is the typical pathway from clinical trials to patient access, however, there may be variations in this process.

To learn more, visit:

Health Canada, Clinical Trials and Drug Safety, Accessed August 2021
Health Canada, Notice of Compliance for Drug Products, Accessed August 2021
Canadian Agency for Drug Technologies and Health, About the Health Technology Assessment
Service, Accessed August 2021

 

Special thanks

ESC thanks the patient volunteers and expert consultants for their review and feedback.
 
ESC acknowledges the following funders for their support of this project: AbbVie Canada, Eli Lilly Canada Inc., LEO Pharma Inc., Pfizer Canada, and Sanofi Genzyme, a division of sanofi-aventis Canada Inc.